Zolpidem and Driving Impairment

    Volume 46, Issue 1 (January 2001)

    ISSN: 0022-1198

    CODEN: JFSOAD

    Page Count: 6


    Logan, BK

    Couper, FJ
    Washington State Toxicology Laboratory, University of Washington, Seattle, WA

    (Received 5 January 2000; accepted 7 March 2000)

    Abstract

    Zolpidem, a non-benzodiazepine hypnotic, was identified in the blood of 29 subjects arrested for impaired driving. Zolpidem concentrations ranged from 0.05 to 1.4 mg/L (mean 0.29 mg/L, median 0.19 mg/L). In the subjects whose cases we reviewed where zolpidem was present with other drugs and/or alcohol, symptoms reported were generally those of CNS depression. Symptoms included slow movements and reactions, slow and slurred speech, poor coordination, lack of balance, flaccid muscle tone, and horizontal and vertical gaze nystagmus. In five separate cases, where zolpidem was the only drug detected (0.08–1.40 mg/L, mean 0.65 mg/L, median 0.47 mg/L), signs of impairment included slow and slurred speech, slow reflexes, disorientation, lack of balance and co-ordination, and “blacking out.” Although no quantitative relationship between blood concentrations and degree of driving impairment is currently possible, it is reasonable to conclude that because of its specific activity as a sleep inducer, blood concentrations consistent with therapeutic doses of zolpidem have the potential to affect driving in a negative way, and that concentrations above the normal therapeutic range would further impair a person's level of consciousness and driving ability.


    Paper ID: JFS14919J

    DOI: 10.1520/JFS14919J

    ASTM International
    is a member of CrossRef.

    Author
    Title Zolpidem and Driving Impairment
    Symposium , 0000-00-00
    Committee E30